On August 1, 2023, at a meeting of the Board of Directors of Teva Pharmaceutical Industries Ltd., the Board elected Prof. Varda Shalev to serve as a member of the Board, effective September 1, 2023, until Teva?s 2024 annual meeting of shareholders. The Board determined that Prof. Shalev qualifies as an independent director under the listing rules of the New York Stock Exchange. Prof. Shalev is a healthcare executive, medical researcher, and digital health investor with 30 years of experience in primary care, medical informatics, and health technology.

Since 2022, Prof. Shalev has been a Managing Partner at Team8 Health. Since 2020, she has also been a Co-Founder and an Advisory Board Member at Alike.Health. Prof. Shalev has been a Full Professor of Epidemiology at the Tel Aviv University School of Public Health since 2013 and an active primary care physician since 1993.

Prior to her current roles, Prof. Shalev founded and led KSM. She also founded the largest Biobank in Israel at Maccabi Healthcare Services. Prof. Shalev has served as a board member at BATM Advanced Communications Ltd. since 2019 and at Novolog Pharm up 1966 Ltd. since 2022.

Prof. Shalev has declared in writing that she possesses the requisite skills and expertise, as well as sufficient time, to perform her duties as a director of Teva, as required pursuant to the Israeli Companies Law, 5759-1999.